Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2023-04-21 Annual Report
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2023-04-21 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the Annual Meeting of Stockholders, including proposals to elect directors, advisory votes on executive compensation, and ratification of the independent auditor. The document is titled 'Proxy Statement' and contains detailed proxy materials for shareholder voting. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, as well as proxy materials related to such matters. The document length is 4136 characters, which is consistent with a proxy statement or related materials. Therefore, the correct classification is DEF 14A with high confidence.
2023-04-21 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-21 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 18, 2023. It includes disclosures about a conference call and webcast to discuss initial clinical data, accompanied by a slide presentation (Exhibit 99.1), and a press release (Exhibit 99.2). The document explicitly states that the presentation is furnished and not filed, and the content is primarily an announcement of events and materials related to a clinical data presentation. The document length is 4179 characters, which is relatively short and consistent with an announcement rather than a full report. There are no detailed financial statements or substantive financial data included. The nature of the content aligns with an Investor Presentation (IP) since it involves a slide presentation for investors focusing on clinical data and company updates. Therefore, the best classification is Investor Presentation (IP).
2023-04-18 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-28 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.